Transmitted HIV-1 Drug Resistance in a Treatment-Naive Cohort of Recently Infected Individuals from Chennai, India

AIDS Res Hum Retroviruses. 2019 Aug;35(8):775-779. doi: 10.1089/AID.2019.0022. Epub 2019 May 29.

Abstract

A cross-sectional study was undertaken to examine the prevalence and pattern of HIV drug resistance mutations (DRMs) among recently HIV-1-infected and antiretroviral therapy (ART)-naive individuals from Chennai, South India. The HIV-1 pol gene encompassing the protease and reverse transcriptase (RT) regions were analyzed from 53 ART-naive HIV-1-infected individuals using an in-house method for identifying DRMs by genotyping. The overall prevalence of transmitted drug resistance (TDR) was found to be 11.3% (6/53), which is categorized as moderate level (5.0%-15.0%) of TDR according to the World Health Organization (WHO) survey guidelines. Surveillance drug resistance mutations to non-nucleoside reverse transcriptase inhibitors (NNRTI) were observed in 8.3% (n = 4) of the 48 RT sequences analyzed. No major DRMs related to the protease and nucleoside reverse transcriptase inhibitor (NRTIs) class of drugs were identified.

Keywords: ART-naive; HIV drug resistance; antiretroviral resistance; human immunodeficiency virus type-1; transmitted drug resistance.

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Cross-Sectional Studies
  • Drug Resistance, Viral / genetics*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / drug effects*
  • HIV-1 / genetics*
  • Humans
  • India
  • Male
  • Phylogeny
  • Protease Inhibitors / therapeutic use
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Young Adult
  • pol Gene Products, Human Immunodeficiency Virus / genetics

Substances

  • Anti-HIV Agents
  • Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • pol Gene Products, Human Immunodeficiency Virus